Biotech News

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

Catalyst Biosciences (CBIO)Catalyst Biosciences2025-10-14 11:00 ESTClinical readout

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that it will be presenting results from

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

CBIOCatalyst Biosciences2026-08-07 11:00 EST

Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update

CBIOCatalyst Biosciences2026-07-16 20:05 EST

Gyre Therapeutics Appoints Three New Members to its Board of Directors

CBIOCatalyst Biosciences2026-05-12 20:06 EST

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

CBIOCatalyst Biosciences2026-05-07 10:00 EST

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

CBIOCatalyst Biosciences2026-05-04 12:48 EST

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Stock data

Close: 17.15 USD
Market cap: 468.91M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States